Discovery of First-in-Class hCA II/ROCK Dual Inhibitors with Both IOP-Lowering and Retinal Neuroprotective Activities for the Treatment of Glaucoma

Glaucoma is the leading cause of irreversible blindness worldwide. Current first-line therapies frequently yield suboptimal intraocular pressure (IOP) control. Furthermore, many patients develop progressive visual field loss despite adequate pressure management. To address this gap, we developed a class of first-in-class dual-target inhibitors against carbonic anhydrase II (CA II) and Rho-associated coiled-coil-containing protein kinase (ROCK). Among them, A3 showed 6250-fold higher hCA II inhibitory potency than the initial fragment with favorable selectivity and 1.2-/1.7-fold higher ROCK1/2 inhibitory activity than fasudil. In vivo, A3 produced potent and sustained IOP reduction across multiple models. Notably, in the DBA/2J spontaneous glaucoma model, it potently lowered IOP and preserved retinal structural integrity. Meanwhile, A3 attenuated retinal ganglion cell apoptosis via its antioxidant and anti-inflammatory effects, thereby conferring optic neuroprotection with favorable systemic safety. Overall, A3 overcomes key limitations of current antiglaucoma drugs and represents a promising candidate for combined IOP-lowering and optic neuroprotective therapy.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-11-20
DOI
https://doi.org/10.1021/acs.jmedchem.6c02537
Primary Topic
Glaucoma and retinal disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Discovery of First-in-Class hCA II/ROCK Dual Inhibitors with Both IOP-Lowering and Retinal Neuroprotective Activities for the Treatment of Glaucoma

Zhuang Hou, 郭春, 孟璧 郭, Yu Zheng et al.
2 links
Journal of Medicinal Chemistry
Glaucoma and retinal disorders
article

Discovery of First-in-Class hCA II/ROCK Dual Inhibitors with Both IOP-Lowering and Retinal Neuroprotective Activities for the Treatment of Glaucoma

Zhuang Hou, 郭春, 孟璧 郭, Yu Zheng, Yitong Wang, Manru Wang, Zhongyu Liu, Lixia Qin, Yanhua Mou, Cheng Peng, Haoying Li, Xin Wang
article en

Abstract

Glaucoma is the leading cause of irreversible blindness worldwide. Current first-line therapies frequently yield suboptimal intraocular pressure (IOP) control. Furthermore, many patients develop progressive visual field loss despite adequate pressure management. To address this gap, we developed a class of first-in-class dual-target inhibitors against carbonic anhydrase II (CA II) and Rho-associated coiled-coil-containing protein kinase (ROCK). Among them, A3 showed 6250-fold higher hCA II inhibitory potency than the initial fragment with favorable selectivity and 1.2-/1.7-fold higher ROCK1/2 inhibitory activity than fasudil. In vivo, A3 produced potent and sustained IOP reduction across multiple models. Notably, in the DBA/2J spontaneous glaucoma model, it potently lowered IOP and preserved retinal structural integrity. Meanwhile, A3 attenuated retinal ganglion cell apoptosis via its antioxidant and anti-inflammatory effects, thereby conferring optic neuroprotection with favorable systemic safety. Overall, A3 overcomes key limitations of current antiglaucoma drugs and represents a promising candidate for combined IOP-lowering and optic neuroprotective therapy.

Journal of Medicinal Chemistry
Shenyang Pharmaceutical University (CN), Fourth Affiliated Hospital of China Medical University (CN)
National Natural Science Foundation of China, Natural Science Foundation of Liaoning Province, Department of Education of Liaoning Province, Liaoning Revitalization Talents Program
Good health and well-being
Glaucoma and retinal disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Discovery of First-in-Class hCA II/ROCK Dual Inhibitors with Both IOP-Lowering and Retinal Neuroprotective Activities for the Treatment of Glaucoma — Zhuang Hou, 郭春, et al. · Journal of Medicinal Chemistry (2026) | TGRS Research Map | TGRS